Quarterly report pursuant to Section 13 or 15(d)

Aytu Divestiture - Summary of Income Statement (Details)

v3.20.2
Aytu Divestiture - Summary of Income Statement (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Other (expense) income:        
Change in value of Guarantee $ 0   $ 1,755,000 $ 0
Pediatric Portfolio | Discontinued Operations, Disposed of by Sale        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Product revenue, net (197,505) $ 3,412,044 (1,370,310) 9,304,580
Operating expenses:        
Cost of product sales 0 1,302,679 0 3,852,878
General and administrative 0 41,374 0 124,121
Sales and marketing 0 2,416,338 0 7,739,955
Amortization expense 0 702,665 0 2,190,865
Impairment of intangible assets 0 0 0 1,449,121
Change in fair value of contingent consideration 0 (197,219) 0 247,042
Total operating expenses 0 4,265,837 0 15,603,982
Other (expense) income:        
Change in value of Guarantee 0 0 1,755,000 0
Interest expense, net 0 (238,158) 0 (714,473)
Total other (expense) income 0 (238,158) 1,755,000 (714,473)
(Loss) income from discontinued operations before tax (197,505) (1,091,951) 384,690 (7,013,875)
Income tax (benefit) expense 0 (5,989) 0 42,668
(Loss) income from discontinued operations, net of tax $ (197,505) $ (1,085,962) $ 384,690 $ (7,056,543)